UC2AR081032

Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core - Project Summary

The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmune and Immune-Mediated Diseases (AMP AIM) is poised to expand the understanding of the cellular components and interactions at play in four autoimmune disease target tissues with new spatially-oriented modalities of single-cell analyses.

As in the AMP1, the AMP AIM will require high-quality samples for interrogation, standardized methods to assess sample quality, and common molecular/phenotypic biomarker testing across all subjects for a clinically and molecularly well-phenotyped cohort to apply new cutting-edge technologies to re-construct disease.

The OMRF Tissue Research Core (TRC) is uniquely positioned to successfully deploy a centralized TRC across all disease teams for Lupus (SLE), RA, Sjogren's Disease (SJD), and Psoriatic Spectrum Diseases (PSD). With a robust, existing infrastructure, capabilities, and leadership, the OMRF TRC will provide the network with:

1) Standardized protocols and manuals to be used across all parts of the network,
2) Centralized logistics for collection, transport, storage, and dissemination,
3) Centralized, trans-disease QC and initial testing of all samples in a continuous manner as samples are collected for early quality management and identification of samples of high importance,
4) Tissue imaging (basic histology & initial high-dimensional) utilizing sample sparing workflows that provide scoring and QC of tissue, plus initial multi-omic, spatially-informed data sets, and
5) Industry standard repository and image database systems.

The OMRF TRC is centrally located, making it an ideal location for logistics management and, since it was the repository for AMP1, carries network knowledge along with extensive experience as a repository for multiple other national consortia, providing continuity during the transition to AMP AIM.

The OMRF TRC already has infrastructure in place and the reputation that follows from strong leadership to continue to act as an ideal honest broker for the network. The OMRF TRC has state-of-the-art facilities that are integrated with advanced technologies within its associated cores to receive, store, collect meaningful QC and initial data sets, and disseminate selected samples to technology and analytic cores (TAC) poised to provide data from emerging technologies to build upon the deep clinical and initial characterization data, to make extremely high-dimensional, robust datasets.

Considering the longstanding history of the OMRF TRC in biobanking samples for autoimmune disease studies, the OMRF TRC is poised to produce a solid foundation of banked samples, organized logistics, and initial multi-omic datasets that will set up the network for success in reconstructing our mechanistic understanding and clinical application of these new data to better treat these autoimmune diseases.

Oklahoma Medical Research Foundation

THE NATIONAL INSTITUTE OF AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS) MISSION IS TO SUPPORT RESEARCH INTO THE CAUSES, TREATMENT, AND PREVENTION OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES, TRAINING OF BASIC AND CLINICAL SCIENTISTS TO CARRY OUT THIS RESEARCH, AND DISSEMINATION OF INFORMATION ON RESEARCH PROGRESS IN THESE DISEASES. THE EXTRAMURAL PROGRAM PROMOTES AND SUPPORTS BASIC, TRANSLATIONAL, AND CLINICAL STUDIES OF SYSTEMIC RHEUMATIC AND AUTOIMMUNE DISEASES, SKIN BIOLOGY AND DISEASES, BONE BIOLOGY AND DISEASES, MUSCLE BIOLOGY AND DISEASES, AND JOINT BIOLOGY AND DISEASES AND ORTHOPAEDICS. NIAMS SYSTEMIC RHEUMATIC AND AUTOIMMUNE DISEASES PROGRAMS ADDRESS BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH, INCLUDING CLINICAL TRIALS AND OBSERVATIONAL AND MECHANISTIC STUDIES, FOCUSED ON IMMUNE-MEDIATED ARTHRITIS AND AUTOIMMUNE-RELATED ACUTE AND CHRONIC DISORDERS IN ADULTS AND CHILDREN. NIAMS SKIN BIOLOGY AND DISEASES PROGRAMS SUPPORT BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH IN SKIN, INCLUDING BOTH COMMON AND RARE SKIN DISEASES. THESE PROGRAMS INCLUDE INVESTIGATIONS OF THE BASIC MOLECULAR, CELLULAR, AND DEVELOPMENTAL BIOLOGY OF SKIN, AS WELL AS STUDIES OF SKIN AS AN IMMUNE, SENSORY, ENDOCRINE, AND METABOLIC ORGAN. NIAMS BONE BIOLOGY AND DISEASES PROGRAMS SUPPORT RESEARCH ON THE CONTROL OF BONE FORMATION, RESORPTION, AND MINERALIZATION AS WELL AS THE EFFECTS OF SIGNALING MOLECULES ON BONE CELLS. THEY SUPPORT CLINICAL STUDIES OF INTERVENTIONS TO PREVENT FRACTURES ASSOCIATED WITH OSTEOPOROSIS AND RESEARCH INTO LESS COMMON BONE DISEASES. NIAMS MUSCLE BIOLOGY AND DISEASES PROGRAMS ENCOURAGE RESEARCH ON MUSCLE DEVELOPMENTAL BIOLOGY, GROWTH, MAINTENANCE, AND HYPERTROPHY, PHYSIOLOGY OF CONTRACTION, STRUCTURAL BIOLOGY OF THE CONTRACTILE APPARATUS, DISEASE MECHANISMS, BIOMARKERS AND OUTCOME MEASURES, AND DEVELOPMENT AND CLINICAL TESTING OF THERAPIES FOR CONDITIONS INCLUDING THE MUSCULAR DYSTROPHIES. NIAMS JOINT BIOLOGY, DISEASES, AND ORTHOPAEDICS PROGRAMS SUPPORT A BROAD SPECTRUM OF RESEARCH CENTERED ON THE INTERPLAY AMONG THE BODY'S MUSCLES, BONES, AND CONNECTIVE TISSUES. THEY ENCOURAGE TISSUE ENGINEERING AND REGENERATIVE MEDICINE RESEARCH, MOLECULAR BIOLOGY, IMAGING, AND CLINICAL RESEARCH, AND THE TREATMENT AND PREVENTION OF ORTHOPAEDIC CONDITIONS. NIAMS PARTICIPATES IN THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS. THE SBIR PROGRAM IS INTENDED TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE STTR PROGRAM IS INTENDED TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.867 - Vision Research

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [HHS - NIH]

National Eye Institute (NEI) [HHS - NIH]

Oklahoma United States

State-Wide

Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed) (RFA-AR-21-016)

Amendment Since initial award the total obligations have increased 760% from $2,279,549 to $19,601,747.